FDA Approves Iberdomide Combo for Multiple Myeloma

Published Date: 17 Aug 2026

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Read Full News

Latest News

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Todays Updates

Adrenal Incidentalomas: When to Worry and What to Test

Not all adrenal incidentalomas need the same workup. The Curbsiders break down when to worry, what to test, and why MACS may be behind your patient's hard-to-control metabolic disease.

Understanding the 'Wait Time Paradox' in Ovarian Cancer

Dr Maurie Markman examines new registry data on ovarian cancer diagnostic timing, showing how disease biology can complicate the link between early detection and survival.

Adapting Approaches in the Fibromyalgia Landscape

Dr Andrea Chadwick describes how the shift from tender points to symptom-based criteria has improved fibromyalgia diagnosis, understanding, and patient-centered care.

The Expanding Use of CGM for Diabetes

Dr Anne Peters discusses the expanding use of continuous glucose monitoring in people with diabetes.

Four Signs You Should Biopsy a Skin Lesion, Not Freeze It

Before you freeze a skin lesion, ask yourself whether you really know what it is. Here are four signs you should biopsy instead of freeze.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

FDA Approves Brain-imaging Agent for Alzheimer's Assessment

The FDA has approved a radioactive agent for use ⁠in brain scans to help assess patients for Alzheimer's disease.

Todays Updates

Adrenal Incidentalomas: When to Worry and What to Test

Not all adrenal incidentalomas need the same workup. The Curbsiders break down when to worry, what to test, and why MACS may be behind your patient's hard-to-control metabolic disease.

Understanding the 'Wait Time Paradox' in Ovarian Cancer

Dr Maurie Markman examines new registry data on ovarian cancer diagnostic timing, showing how disease biology can complicate the link between early detection and survival.

Adapting Approaches in the Fibromyalgia Landscape

Dr Andrea Chadwick describes how the shift from tender points to symptom-based criteria has improved fibromyalgia diagnosis, understanding, and patient-centered care.

The Expanding Use of CGM for Diabetes

Dr Anne Peters discusses the expanding use of continuous glucose monitoring in people with diabetes.

Four Signs You Should Biopsy a Skin Lesion, Not Freeze It

Before you freeze a skin lesion, ask yourself whether you really know what it is. Here are four signs you should biopsy instead of freeze.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

FDA Approves Brain-imaging Agent for Alzheimer's Assessment

The FDA has approved a radioactive agent for use ⁠in brain scans to help assess patients for Alzheimer's disease.

Latest News

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

News All Time

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

Recommended News For You

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

How access to specialized cancer centers affects glioblastoma outcomes

Study suggests exercise could reduce breast cancer recurrence

Liver cancer survival rates reflect income disparities

US Mental Health Treatment Rates Rise But Gaps Persist

Recommended Articles For You

Emerging Models in Oncology for Specialists 

Adaptive Rehabilitation Strategies for Advanced Cancer Survivorship 

Progressive Models in Hematology for Healthcare Excellence 

Living Well After Cancer: Building Long-Term Personal Resilience 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Guidelines for cervical cancer screening and the risk of preterm birth in young women.

2.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

3.

Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia

4.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

5.

Health researchers discuss Medicaid cancer screening trends, best practices

1.

The Risk Factors of Venous Thromboembolism and How to Lower Your Chances 

2.

Precision Oncology Using Tumor Evolutionary Trajectory Modeling

3.

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care

4.

HKDC1 Protein: An Emerging Therapeutic Target in Colon Cancer

5.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

5.

Latest Advances in Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot